Novo Nordisk (NYSE:NVO) closed the most recent trading day at $97.12, showcasing a positive change of +0.86% compared to the previous trading session. This performance outshone the S&P 500’s slight daily loss of 0.17%. In contrast, the Dow experienced a 0.58% decline, while the tech-heavy Nasdaq added 0.27%.
Over the past month, shares of this pharmaceutical company have surged by 5.47%. This impressive gain surpassed the performance of the Medical sector, which experienced a 5.22% loss during the same period, as well as the broader S&P 500’s 3.95% decline.
Investors and analysts are closely watching Novo Nordisk’s upcoming earnings disclosure, set to be made public on November 2, 2023. Projections indicate an expected EPS of $0.58, representing a substantial 34.88% increase compared to the same quarter in the previous year.
Furthermore, it’s essential for investors to monitor any recent revisions in analyst forecasts for Novo Nordisk. These revisions typically reflect short-term business trends that can change frequently. Positive revisions in estimates convey analysts’ confidence in the company’s business performance and profit potential.
Research shows a strong correlation between estimate revisions and near-term share price momentum. To capitalize on this, the Zacks Rank, a proprietary model that incorporates these estimate changes, provides an actionable rating system.
In terms of valuation, Novo Nordisk currently trades with a Forward P/E ratio of 43.94. This valuation represents a premium compared to the industry’s average Forward P/E of 15.16.
Additionally, NVO has a PEG ratio of 1.75, similar to the widely recognized P/E ratio, the PEG ratio accounts for projected earnings growth. The Large Cap Pharmaceuticals industry, to which Novo Nordisk belongs, had an average PEG ratio of 1.75 as of the previous close.
Investors should take these factors into account when assessing Novo Nordisk’s performance and prospects in the pharmaceutical sector.
Featured Image: Freepik
